@article {TAKEUCHI5489, author = {AKIRA TAKEUCHI and TETSUYA OGURI and YORIKO YAMASHITA and KAZUKI SONE and SATOSHI FUKUDA and OSAMU TAKAKUWA and TAKEHIRO UEMURA and KEN MAENO and KENSUKE FUKUMITSU and YOSHIHIRO KANEMITSU and HIROTSUGU OHKUBO and MASAYA TAKEMURA and YUTAKA ITO and AKIO NIIMI}, title = {TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer}, volume = {38}, number = {9}, pages = {5489--5495}, year = {2018}, doi = {10.21873/anticanres.12882}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: To investigate whether TTF-1 expression predicts a beneficial response of non-squamous non-small-cell lung cancer (NS-NSCLC) patients to bevacizumab. Patients and Methods: We retrospectively screened 118 advanced NS-NSCLC patients who were treated with pemetrexed plus platinum derivatives alone (Bev(-)) or with bevacizumab (Bev(+)), and investigated the relationship between expression of TTF-1 and treatment outcomes. Results: Among the 92 TTF-1-positive patients, clinical outcomes in the Bev(+) group were significantly better than those in the Bev(-) group (response rate, 51.4\% vs. 27.3\%, p=0.027; median progression-free survival, 216 days vs. 137 days, p=0.012). Overall survival in the Bev(+) group tended to be longer than that in the Bev(-) group. However, the addition of bevacizumab to the standard treatment of 26 TTF-1-negative patients offered no clinical benefit. Conclusion: TTF-1 expression may serve as a predictive marker to identify patients who may benefit from the addition of bevacizumab to platinum doublet therapy.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/9/5489}, eprint = {https://ar.iiarjournals.org/content/38/9/5489.full.pdf}, journal = {Anticancer Research} }